Home > Riviste > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Fascicoli precedenti > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2008 June;52(2) > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2008 June;52(2):145-50

ULTIMO FASCICOLO
 

ARTICLE TOOLS

Estratti

THE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Rivista di Medicina Nucleare e Imaging Molecolare


A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the Society of Radiopharmaceutical Sciences and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,413


eTOC

 

FOREWORD  NON-STANDARD PET NUCLIDES


The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2008 June;52(2):145-50

Copyright © 2008 EDIZIONI MINERVA MEDICA

lingua: Inglese

Production and separation of “non-standard” PET nuclides at a large cyclotron facility: the experiences at the Paul Scherrer Institute in Switzerland

Hohn A., Zimmermann K., Schaub E., Hirzel W., Schubiger P. A., Schibli R.

Center of Radiopharmaceutical Science Paul Scherrer Institut Villigen PSI, Switzerland


FULL TEXT  


Radioimmuno-positron emission tomography (PET) combined with radioimmunotherapy is attractive to assess tumor targeting and quantitate the radiation dose to tumor and normal tissues. For this purpose, PET radionuclides with adequate physical half-lives matching those of the targeting molecule (e.g. antibodies) are preferable. Copper-64 (T1/2=12.7 h, Eβ+max=653 keV) and Zirconium-89 (T1/2=78.4 d, Eβ+max=901 keV) are attractive isotopes for this purpose. The 72 MeV cyclotron at the Paul Scherrer Institute provides the infrastructure for the production of a wide variety of radionuclides for diagnostic and therapeutic purposes. 64Cu and 89Zr are currently evaluated at the Center for Radiopharmaceu-tical Science (CRS) of the Paul Scherrer Institute (PSI) in combination with the L1 cam targeting antibody chCE7 and various protein formats thereof. A second focus of the CRS is the radiolabeling of small, tumor targeting molecules with technetium. The PET isotope 94mTc offers potential alternative to its widely used 99mTc SPECT counterpart. In this report, the development, optimization and pitfalls of 64Cu, 89Zr and 94mTc production/separation are reported and discussed.

inizio pagina

Publication History

Per citare questo articolo

Corresponding author e-mail